|
|
|
 |
| Location: Home -
Products - API Intermediates - API Intermediates
|
Avasimibe(CI-1011,PD 148515)
| Catalogue No. : |
C13341 |
| Product Name: |
Avasimibe(CI-1011,PD 148515) |
| Synonym: |
CI-1011;PD 148515 |
| Chemical Name: |
N-(2,6-Dipropan-2-ylphenoxy)sulfonyl-2-(2,4,6-tripropan-2-ylphenyl)acetamide;[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester] sulfamic acid |
| CAS No. : |
166518-60-1 |
| Structure : |
|
| Molecular Formula: |
C29H43NO4S |
| Molecular Weight: |
501.72 |
| Purity: |
>99% |
| Usage: |
Avasimibe (CI-1011) is an orally bioavailable Acyl-CoA:Cholesterol O-Acyltransferase (ACAT) inhibitor. It was originally developed as an antilepic drug, and was shown to significantly reduce plasma total triglyceride and VLDL-cholesterol, but later clinical trials were disappointing. ACAT has also been investigated as a potential therapeutic target for Alzheimer′s disease. Recent studies have looked at the effects of avasimibe in reducing amyloid pathology by limiting generation and increasing clearance of diffusible amyloid-beta (Abeta). |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
